IL-10 promoter gene polymorphisms and sustained response to combination therapy in Taiwanese chronic hepatitis C patients
- 30 June 2009
- journal article
- research article
- Published by Elsevier BV in Digestive and Liver Disease
- Vol. 41 (6), 424-430
- https://doi.org/10.1016/j.dld.2008.09.017
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot studyHepatology, 2004
- Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis CAnnals of Internal Medicine, 2004
- IL-10 haplotypes as possible predictors of spontaneous clearance of HCV infectionCytokine, 2004
- Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CHepatology, 2003
- Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus InfectionNew England Journal of Medicine, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- Interleukin-10 and the Interleukin-10 ReceptorAnnual Review of Immunology, 2001
- Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALTJournal of Hepatology, 1999
- Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis CGastroenterology, 1996